scholarly journals Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Michal Pochopien ◽  
Annette Beiderbeck ◽  
Phil McEwan ◽  
Richard Zur ◽  
Mondher Toumi ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Fluocinolone Acetonide ◽  
Fluocinolone Acetonide Implant

scholarly journals Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review

2018 ◽  
Vol 47 (1) ◽  
pp. 31-43 ◽  
Author(s):  
Horace Massa ◽  
Anindyt M. Nagar ◽  
Athanasios Vergados ◽  
Panagiotis Dadoukis ◽  
Sudeshna Patra ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Diabetic Macular Oedema ◽  
Fluocinolone Acetonide ◽  
Vascular Endothelial ◽  
Common Complication ◽  
Severe Visual Loss ◽  
Fluocinolone Acetonide Implant ◽  
Endothelial Growth Factor ◽  
Review Current

Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.

scholarly journals Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study

Eye ◽  
2021 ◽  
Author(s):  
Clare Bailey ◽  
◽  
Usha Chakravarthy ◽  
Andrew Lotery ◽  
Geeta Menon ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Clinical Effectiveness ◽  
Fluocinolone Acetonide ◽  
Prior History ◽  
Foveal Thickness ◽  
Central Foveal Thickness ◽  
Laser Trabeculoplasty ◽  
Retrospective Audit ◽  
History Of

Abstract Background This study aimed to assess the long-term effectiveness of the 0.2 μg/day fluocinolone acetonide (FAc) implant over ≥3 years for patients with diabetic macular oedema. Methods A retrospective audit of pseudo-anonymised data from patients with chronic diabetic macular oedema (cDMO) and treated with the FAc implant across 14 UK clinical sites. Safety and clinical effectiveness were measured. Results Two-hundred and fifty-six eyes had ≥3 years of follow-up (mean 4.28 years), during which a mean of 1.14 FAc implants were used per eye. Mean best-recorded visual acuity (BRVA) increased from 52.6 to 56.7 letters at month 3 and remained stable thereafter; this trend was also seen in pseudophakic eyes. The proportion of patients attaining a BRVA ≥6/12 increased from 17% at baseline to 27% 1 month after FAc implant and remained stable above 30% from month 12 onwards. Eyes with no prior history of intraocular pressure (IOP)-related events required significantly less treatment-emergent IOP-lowering medication than those with a prior history of IOP events (17.9% vs. 50.0% of eyes; p < 0.001). The incidence of an IOP increase of ≥10 mmHg, use of IOP-lowering medication, laser trabeculoplasty and IOP-lowering surgery was 28.9%, 29.7%, 0.8% and 2.7%, respectively, for the whole cohort. There were significant reductions in mean central foveal thickness and macular volume (p < 0.001). Conclusions The FAc implant was well tolerated, with predictable and manageable IOP-related events while delivering a continuous microdose of corticosteroid to eyes with cDMO, providing prolonged vision preservation and a reduced number of treatments.

Visual Function and Structure Outcomes in a Patient with Diabetic Macular Oedema Insufficiently Responsive to Available Therapies – Treatment with Fluocinolone Acetonide Implant

2014 ◽  
Vol 08 (02) ◽  
pp. 137
Author(s):  
Érica ABC Guerreiro Paulo ◽  
Claus Eckardt ◽  
◽  
Keyword(s):  
Visual Function ◽  
Macular Oedema ◽  
Therapeutic Option ◽  
Diabetic Macular Oedema ◽  
Fluocinolone Acetonide ◽  
Eye Drops ◽  
Short Term ◽  
Patient Reported ◽  
Before And After ◽  
Insufficient Response

Importance:Early experience with intraocular, non-biodegradable fluocinolone acetonide (FAc) (0.2 μg/day) implant (ILUVIEN®), comparing visual function before and after treatment in an insufficiently responsive diabetic macular oedema (DMO) patient.Observations:This 62-yearold male patient with type 2 diabetes mellitus was first treated for DMO in 2004, when best corrected visual acuity (BCVA) was 0.8 for his right eye. He did not visit an ophthalmologist again until 2011 when BCVA had declined to 0.2. Three separate, monthly intravitreal (IV) ranibizumab injections and additional laser photocoagulation resulted in no improvement. Subsequently, 0.7 mg IV dexamethasone was administered, giving short-term DMO improvement. However, six further IV ranibizumab injections produced no effect and a combined injection of IV ranibizumab with 0.7 mg IV dexamethasone provided only short-term improvements. Following phacoemulsification, a 0.2 μg/day FAc implant was administered. Optical coherence tomography (OCT) indicated complete DMO regression after 3 weeks, sustained 6 months post-implant. BCVA improved to 0.25 and the patient reported greater vision-related quality of life. Intraocular pressure increased gradually but resolved with daily timolol/dorzolamide and tafluoprost eye drops.Conclusions and relevance:In a DMO patient showing insufficient response to IV ranibizumab and dexamethasone injections, FAc implant provided an effective therapeutic option with manageable side effects.

Sign in / Sign up

Export Citation Format

Share Document